{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T17:12:34Z","timestamp":1776532354339,"version":"3.51.2"},"reference-count":58,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.eprac.2021.06.015","type":"journal-article","created":{"date-parts":[[2021,7,10]],"date-time":"2021-07-10T01:02:58Z","timestamp":1625878978000},"page":"1082-1092","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Meta-Analysis of Clinical Fracture Risk Reduction of Antiosteoporosis Drugs: Direct and Indirect Comparisons and Meta-Regressions"],"prefix":"10.1016","volume":"27","author":[{"given":"Stewart G.","family":"Albert","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily","family":"Wood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.eprac.2021.06.015_bib1","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1210\/jc.2019-00221","article-title":"Pharmacological management of osteoporosis in postmenopausal women: an Endocrine Society clinical practice guideline","volume":"104","author":"Eastell","year":"2019","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"18","key":"10.1016\/j.eprac.2021.06.015_bib2","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa067312","article-title":"Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis","volume":"356","author":"Black","year":"2007","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.eprac.2021.06.015_bib3","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1056\/NEJMcp1513724","article-title":"Clinical practice. Postmenopausal osteoporosis","volume":"374","author":"Black","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.eprac.2021.06.015_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11657-016-0278-z","article-title":"A systematic review of intervention thresholds based on FRAX\u202f: a report prepared for the National Osteoporosis Guideline Group and the International Osteoporosis Foundation","volume":"11","author":"Kanis","year":"2016","journal-title":"Arch Osteoporos"},{"issue":"6","key":"10.1016\/j.eprac.2021.06.015_bib5","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1210\/jc.2011-3060","article-title":"Clinical review. Comparative effectiveness of drug treatments to prevent fragility fractures: a systematic review and network meta-analysis","volume":"97","author":"Murad","year":"2012","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.eprac.2021.06.015_bib6","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1210\/jc.2019-00192","article-title":"Efficacy of pharmacological therapies for the prevention of fractures in postmenopausal women: a network meta-analysis","volume":"104","author":"Barrionuevo","year":"2019","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.eprac.2021.06.015_bib7","doi-asserted-by":"crossref","first-page":"dgaa048","DOI":"10.1210\/clinem\/dgaa048","article-title":"Pharmacological management of osteoporosis in postmenopausal women: an Endocrine Society guideline update","volume":"105","author":"Shoback","year":"2020","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"suppl 1","key":"10.1016\/j.eprac.2021.06.015_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4158\/GL-2020-0524SUPPL","article-title":"American Association of Clinical Endocrinologists\/American College of Endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis-2020 update","volume":"26","author":"Camacho","year":"2020","journal-title":"Endocr Pract"},{"key":"10.1016\/j.eprac.2021.06.015_bib9","doi-asserted-by":"crossref","first-page":"g5630","DOI":"10.1136\/bmj.g5630","article-title":"A GRADE Working Group approach for rating the quality of treatment effect estimates from network meta-analysis","volume":"349","author":"Puhan","year":"2014","journal-title":"BMJ"},{"issue":"18","key":"10.1016\/j.eprac.2021.06.015_bib10","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1056\/NEJMoa074941","article-title":"Zoledronic acid and clinical fractures and mortality after hip fracture","volume":"357","author":"Lyles","year":"2007","journal-title":"N\u00a0Engl J Med"},{"issue":"16","key":"10.1016\/j.eprac.2021.06.015_bib11","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","article-title":"Romosozumab treatment in postmenopausal women with osteoporosis","volume":"375","author":"Cosman","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.eprac.2021.06.015_bib12","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1001\/jama.2016.11136","article-title":"Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial","volume":"316","author":"Miller","year":"2016","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.eprac.2021.06.015_bib13","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1007\/s11657-020-00738-z","article-title":"Teriparatide and bisphosphonate use in osteoporotic spinal fusion patients: a systematic review and meta-analysis","volume":"15","author":"Tsai","year":"2020","journal-title":"Arch Osteoporos"},{"issue":"7","key":"10.1016\/j.eprac.2021.06.015_bib14","doi-asserted-by":"crossref","first-page":"841","DOI":"10.4158\/EP161678.RA","article-title":"Clinical evaluation of cost efficacy of drugs for treatment of osteoporosis: a meta-analysis","volume":"23","author":"Albert","year":"2017","journal-title":"Endocr Pract"},{"issue":"7650","key":"10.1016\/j.eprac.2021.06.015_bib15","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.eprac.2021.06.015_bib17","doi-asserted-by":"crossref","first-page":"A3","DOI":"10.1016\/j.clinthera.2012.12.012","article-title":"New and emerging pharmacologic therapies for type 2 diabetes, dyslipidemia, and obesity","volume":"35","author":"Taylor","year":"2013","journal-title":"Clin Ther"},{"issue":"7","key":"10.1016\/j.eprac.2021.06.015_bib18","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1001\/jama.2015.7032","article-title":"Costs associated with using different insulin preparations","volume":"314","author":"Tylee","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.eprac.2021.06.015_bib19","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/1471-2288-6-50","article-title":"Development and validation of MIX: comprehensive free software for meta-analysis of causal research data","volume":"6","author":"Bax","year":"2006","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.eprac.2021.06.015_bib21","series-title":"Cochrane Handbook for Systematic Review of Intervention","first-page":"243","article-title":"Analysing data and understanding meta-analysis","author":"Deeks","year":"2008"},{"issue":"4","key":"10.1016\/j.eprac.2021.06.015_bib22","first-page":"719","article-title":"Statistical aspects of the analysis of data from retrospective studies of disease","volume":"22","author":"Mantel","year":"1959","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"3","key":"10.1016\/j.eprac.2021.06.015_bib23","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"issue":"2","key":"10.1016\/j.eprac.2021.06.015_bib24","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/0197-2456(90)90005-M","article-title":"Power and sample size calculations. A review and computer program","volume":"11","author":"Dupont","year":"1990","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.eprac.2021.06.015_bib25","unstructured":"PS: Power and Sample Size Calculation, Accessed February 15, 2021. PowerSampleSize < Main < Vanderbilt Biostatistics Wiki (vumc.org)."},{"issue":"5","key":"10.1016\/j.eprac.2021.06.015_bib26","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1056\/NEJM200102013440503","article-title":"Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group","volume":"344","author":"McClung","year":"2001","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.eprac.2021.06.015_bib27","doi-asserted-by":"crossref","first-page":"CR442","DOI":"10.12659\/MSM.881905","article-title":"Teriparatide vs. alendronate as a treatment for osteoporosis: changes in biochemical markers of bone turnover, BMD and quality of life","volume":"17","author":"Panico","year":"2011","journal-title":"Med Sci Monit"},{"issue":"3","key":"10.1016\/j.eprac.2021.06.015_bib28","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1002\/jbmr.238","article-title":"Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis","volume":"26","author":"Cosman","year":"2011","journal-title":"J\u00a0Bone Miner Res"},{"issue":"6","key":"10.1016\/j.eprac.2021.06.015_bib29","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1097\/AOG.0b013e318291718c","article-title":"Denosumab compared with ibandronate in postmenopausal women previously treated with bisphosphonate therapy: a randomized open-label trial","volume":"121","author":"Recknor","year":"2013","journal-title":"Obstet Gynecol"},{"issue":"8","key":"10.1016\/j.eprac.2021.06.015_bib30","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1056\/NEJMoa044459","article-title":"Denosumab in postmenopausal women with low bone mineral density","volume":"354","author":"McClung","year":"2006","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.eprac.2021.06.015_bib31","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.bone.2006.11.001","article-title":"Comparative effects of raloxifene and alendronate on fracture outcomes in postmenopausal women with low bone mass","volume":"40","author":"Recker","year":"2007","journal-title":"Bone"},{"issue":"1","key":"10.1016\/j.eprac.2021.06.015_bib32","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1185\/030079908X253889","article-title":"Once-monthly oral ibandronate compared with weekly oral alendronate in postmenopausal osteoporosis: results from the head-to-head MOTION study","volume":"24","author":"Miller","year":"2008","journal-title":"Curr Med Res Opin"},{"issue":"15","key":"10.1016\/j.eprac.2021.06.015_bib33","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","article-title":"Romosozumab or alendronate for fracture prevention in women with osteoporosis","volume":"377","author":"Saag","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.eprac.2021.06.015_bib34","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1007\/s00198-011-1856-y","article-title":"The effect of teriparatide compared with risedronate on reduction of back pain in postmenopausal women with osteoporotic vertebral fractures","volume":"23","author":"Hadji","year":"2012","journal-title":"Osteoporos Int"},{"issue":"10117","key":"10.1016\/j.eprac.2021.06.015_bib35","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S0140-6736(17)32137-2","article-title":"Effects of teriparatide and risedronate on new fractures in postmenopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial","volume":"391","author":"Kendler","year":"2018","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.eprac.2021.06.015_bib36","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMoa0809493","article-title":"Denosumab for prevention of fractures in postmenopausal women with osteoporosis","volume":"361","author":"Cummings","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.eprac.2021.06.015_bib37","doi-asserted-by":"crossref","first-page":"711","DOI":"10.7326\/M14-0317","article-title":"Comparative effectiveness of pharmacologic treatments to prevent fractures: an updated systematic review","volume":"161","author":"Crandall","year":"2014","journal-title":"Ann Intern Med"},{"issue":"5","key":"10.1016\/j.eprac.2021.06.015_bib38","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1210\/jc.2019-00193","article-title":"Women\u2019s values and preferences regarding osteoporosis treatments: a systematic review","volume":"104","author":"Barrionuevo","year":"2019","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"10","key":"10.1016\/j.eprac.2021.06.015_bib39","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1007\/s00198-008-0712-1","article-title":"Case finding for the management of osteoporosis with FRAX--assessment and intervention thresholds for the UK","volume":"19","author":"Kanis","year":"2008","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.eprac.2021.06.015_bib40","unstructured":"Higgins JPT, Thomas J, Chandler J, et\u00a0al, eds. Cochrane Handbook for Systematic Reviews of Interventions version 6.2. Cochrane; 2021. Updated February 2021. Accessed August 13, 2021. www.training.cochrane.org\/handbook"},{"key":"10.1016\/j.eprac.2021.06.015_bib41","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.jclinepi.2017.10.005","article-title":"Advances in the GRADE approach to rate the certainty in estimates from a network meta-analysis","volume":"93","author":"Brignardello-Petersen","year":"2018","journal-title":"J\u00a0Clin Epidemiol"},{"issue":"8","key":"10.1016\/j.eprac.2021.06.015_bib42","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/S2213-8587(20)30159-5","article-title":"Treatment-related changes in bone mineral density as a surrogate biomarker for fracture risk reduction: meta-regression analyses of individual patient data from multiple randomised controlled trials","volume":"8","author":"Black","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"9041","key":"10.1016\/j.eprac.2021.06.015_bib43","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/S0140-6736(96)07088-2","article-title":"Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures","volume":"348","author":"Black","year":"1996","journal-title":"Lancet"},{"issue":"24","key":"10.1016\/j.eprac.2021.06.015_bib44","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1001\/jama.296.24.2927","article-title":"Effects of continuing or stopping alendronate after 5 years of treatment: The fracture intervention trial long-term extension (flex): a randomized trial","volume":"296","author":"Black","year":"2006","journal-title":"JAMA"},{"issue":"24","key":"10.1016\/j.eprac.2021.06.015_bib45","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1001\/jama.280.24.2077","article-title":"Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial","volume":"280","author":"Cummings","year":"1998","journal-title":"JAMA"},{"issue":"9","key":"10.1016\/j.eprac.2021.06.015_bib46","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1359\/jbmr.1998.13.9.1431","article-title":"Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trial","volume":"13","author":"Greenspan","year":"1998","journal-title":"J Bone Miner Res"},{"issue":"10","key":"10.1016\/j.eprac.2021.06.015_bib47","doi-asserted-by":"crossref","first-page":"742","DOI":"10.7326\/0003-4819-136-10-200205210-00009","article-title":"Alendronate improves bone mineral density in elderly women with osteoporosis residing in long-term care facilities. A randomized, double-blind, placebo-controlled trial","volume":"136","author":"Greenspan","year":"2002","journal-title":"Ann Intern Med"},{"issue":"22","key":"10.1016\/j.eprac.2021.06.015_bib48","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1056\/NEJM199511303332201","article-title":"Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis","volume":"333","author":"Liberman","year":"1995","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.eprac.2021.06.015_bib49","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1210\/jc.2013-4175","article-title":"Clinical Trials Express: fracture risk reduction with denosumab in Japanese postmenopausal women and men with osteoporosis: denosumab fracture intervention randomized placebo controlled trial (DIRECT)","volume":"99","author":"Nakamura","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"10.1016\/j.eprac.2021.06.015_bib50","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1359\/JBMR.040325","article-title":"Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis","volume":"19","author":"Chestnut","year":"2004","journal-title":"J Bone Miner Res"},{"issue":"5","key":"10.1016\/j.eprac.2021.06.015_bib51","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.bone.2004.01.008","article-title":"Insufficiently dosed intravenous ibandronate injections are associated with suboptimal antifracture efficacy in postmenopausal osteoporosis","volume":"34","author":"Recker","year":"2004","journal-title":"Bone"},{"issue":"1","key":"10.1016\/j.eprac.2021.06.015_bib52","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1359\/jbmr.070904","article-title":"Effects of raloxifene on fracture risk in postmenopausal women: the Raloxifene Use for the Heart Trial","volume":"23","author":"Ensrud","year":"2008","journal-title":"J Bone Miner Res"},{"issue":"7","key":"10.1016\/j.eprac.2021.06.015_bib53","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1001\/jama.282.7.637","article-title":"Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial","volume":"282","author":"Ettinger","year":"1999","journal-title":"JAMA"},{"issue":"14","key":"10.1016\/j.eprac.2021.06.015_bib54","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jama.282.14.1344","article-title":"Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: A randomized controlled trial","volume":"282","author":"Harris","year":"1999","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.eprac.2021.06.015_bib55","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s001980050010","article-title":"Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis","volume":"11","author":"Reginster","year":"2000","journal-title":"Osteoporos Int"},{"issue":"19","key":"10.1016\/j.eprac.2021.06.015_bib56","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","article-title":"Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis","volume":"344","author":"Neer","year":"2001","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.eprac.2021.06.015_bib57","doi-asserted-by":"crossref","first-page":"3097","DOI":"10.1210\/jc.2011-3479","article-title":"Randomized Teriparatide [human parathyroid hormone (PTH) 1-34] Once-Weekly Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk","volume":"97","author":"Nakamura","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.eprac.2021.06.015_bib58","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/jbmr.1494","article-title":"The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT)","volume":"27","author":"Black","year":"2012","journal-title":"J Bone Miner Res"},{"issue":"6","key":"10.1016\/j.eprac.2021.06.015_bib59","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1001\/jamainternmed.2015.0747","article-title":"Efficacy and safety of single-dose zoledronic acid for osteoporosis in frail elderly women: a randomized clinical trial","volume":"175","author":"Greenspan","year":"2015","journal-title":"JAMA Intern Med"},{"issue":"8","key":"10.1016\/j.eprac.2021.06.015_bib60","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1056\/NEJMoa044459","article-title":"Denosumab in postmenopausal women with low bone mineral density","volume":"354","author":"McClung","year":"2006","journal-title":"N Engl J Med"}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X21011101?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X21011101?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T22:10:39Z","timestamp":1761516639000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X21011101"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":58,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["S1530891X21011101"],"URL":"https:\/\/doi.org\/10.1016\/j.eprac.2021.06.015","relation":{},"ISSN":["1530-891X"],"issn-type":[{"value":"1530-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Meta-Analysis of Clinical Fracture Risk Reduction of Antiosteoporosis Drugs: Direct and Indirect Comparisons and Meta-Regressions","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eprac.2021.06.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 AACE. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}